TL;DR: 30 июня 2026 Anthropic проводит The Briefing: AI for Science — крупнейший life sciences moment после Claude Code. Nobel laureate John Jumper (AlphaFold co-creator) 19 июня ушёл из Google DeepMind в Anthropic. Claude Mythos 5 drug design ~10× faster, strong compounds на 9/14 protein targets zero human help. Novo Nordisk CSR writing −90%. CEOs Novartis, BMS, Genentech on stage. Guide covers event lineup, Jumper AlphaFold legacy, 18-month Claude for Life Sciences rollout, Mythos 5 benchmarks, Coefficient Bio acquisition, export control status + life sciences FAQ — six context modules pre-livestream.
Это не routine model drop. Anthropic объявляет life sciences следующей major vertical после Claude Code. Шесть hard facts отделяют signal от hype до livestream 30 июня.
Jumper — headline, product — Claude for Life Sciences: Nobel move тянет PR, но real bet — enterprise stack с Benchling, PubMed, 10x Genomics, Medidata; launch Oct 2025, production у Novo Nordisk, Sanofi, AbbVie.
Pharma CEOs on stage = enterprise lock-in: Vas Narasimhan (Novartis CEO + Anthropic board), Chris Boerner (BMS), Aviv Regev (Genentech R&D) — это production deployments, не pilot sandbox.
Mythos 5 benchmarks real, export-controlled: 10× drug design speed, 9/14 autonomous hits — global shutdown 12 июня. На 30 июня только ~100 US critical-infrastructure orgs с partial restore.
Coefficient Bio — скрытый strategic move: ~$400M all-stock acquisition в апреле; sub-10 Genentech Prescient Design alumni — bridge от LLM assistant к drug discovery engine.
18 месяцев deliberate buildup: Claude for Life Sciences (Oct 2025) → Allen Institute partnerships → Karpathy pre-training (May 2026) → Fable/Mythos 5 (Jun 9) — сегодня public capstone.
Developer execution layer всё ещё bottleneck: Claude Code + MCP для toxicity prediction (Axiom) требует stable long-running Agent sessions. 16GB laptop swap на multi-hour genomics pipeline — см. тарифы аренды cloud Mac как execution substrate.
The Briefing: AI for Science — 30 июня 2026, 10:00 AM PST (20:00 MSK) — hybrid event из San Francisco + global livestream.
| Parameter | Value |
|---|---|
| Event name | The Briefing: AI for Science |
| Date & time | 30 June 2026 · 10:00 AM PST |
| Format | San Francisco in-person + global livestream |
| Host | Anthropic (Claude parent co.) |
| Agenda | Life sciences vision, Claude for Life Sciences demos, top pharma customer spotlights |
| Speaker | Role |
|---|---|
| Vas Narasimhan | CEO Novartis; Anthropic board member |
| Chris Boerner, PhD | CEO Bristol Myers Squibb |
| Aviv Regev | EVP & Head of R&D, Genentech |
| Lotte Bjerre Knudsen | Professor, DMSc; ex-Novo Nordisk Chief Scientific Adviser |
| Eric Kauderer-Abrams | Head of Life Sciences, Anthropic |
| Jonah Cool | Head of Life Sciences Partnerships, Anthropic |
| Matthew Herper | Senior Writer, STAT News (moderator) |
Когда CEO Novartis и BMS делят stage с AI company — это не marketing stunt, а vector реального pharma R&D.
John Michael Jumper, b. 1985 Little Rock AR: Vanderbilt (BS math/physics 2007), Cambridge (MPhil physics, Marshall 2008), UChicago (PhD theoretical chemistry 2017).
+6 months post-PhD → Google DeepMind secret project: protein folding 3D structure prediction — open problem с 1970-х.
CASP14 2020: AlphaFold 2 hits experimental-grade accuracy — hours vs months.
| AlphaFold impact | Scale |
|---|---|
| Structures predicted | 214M+ across ~1M species |
| Global adoption | 2M+ users, 190+ countries |
| Applications | Drug discovery, cancer research, molecular biology |
2024: Jumper + Demis Hassabis Nobel Prize in Chemistry (+ David Baker UW). Age 39 — youngest chemistry laureate in 70+ years.
19 June 2026, X post:
“After nearly nine years, I have decided to leave Google DeepMind and join Anthropic.”
Hassabis public reply: “We changed the world with AlphaFold” — AI path for science and medicine.
Timing: 11 days pre-event — deliberate. Specific role TBD. Bloomberg Jun 24: co-authors Adler, Pritzel may follow — unconfirmed.
Strategic fit: Apr 2026 Anthropic acquired Coefficient Bio (~$400M), founders from Genentech computational drug discovery. Jumper sits at intersection foundational biology AI ↔ applied drug design.
Сегодня — public capstone systematic rollout, не day-one pivot.
| Date | Milestone |
|---|---|
| October 2025 | Claude for Life Sciences launch; anchor: Novo Nordisk, Sanofi, AbbVie, AstraZeneca, Genmab |
| February 2026 | Allen Institute + HHMI Janelia research partnerships |
| April 2026 | Coefficient Bio ~$400M (ex-Genentech comp bio team) |
| May 19, 2026 | Andrej Karpathy joins pre-training team |
| June 9, 2026 | Claude Fable 5 + Mythos 5 science capabilities launch |
| June 12, 2026 | US export control: Fable 5/Mythos 5 global shutdown |
| June 19, 2026 | John Jumper DeepMind → Anthropic |
| June 26, 2026 | Mythos 5 partial restore ~100 US orgs |
| June 30, 2026 | The Briefing: AI for Science |
Oct 2025 launch: vertical on Claude Enterprise — MCP connectors + Agent Skills wired в existing scientist toolchain.
| Platform | Claude function |
|---|---|
| Benchling | SOPs, informed consent, protocols from ELN/LIMS |
| 10x Genomics | Single-cell + spatial transcriptomics analysis |
| PubMed | Literature search/retrieve/synthesize + citations |
| bioRxiv / medRxiv | Preprint retrieval + analysis |
| Open Targets | Therapeutic target ID + prioritization |
| Medidata | Clinical trial enrollment + site performance |
| ClinicalTrials.gov | Registry queries + competitive landscape |
| Wiley Scholar Gateway | Full-text journal access |
| BioRender | Scientific image processing |
Internal Anthropic testing: Mythos 5 accelerates key drug design steps ~10×. Zero human assistance study — full scientific workflow end-to-end:
Binding site identification
Protein design tool selection + execution
Autonomous failure recovery
Viable drug candidate output under investigation
Result: 9/14 protein targets (64%) strong candidates — immune checkpoints, growth-factor signaling, neurodegeneration, muscle disease, complex structural targets.
Novo Nordisk (Ozempic mfg) built NovoScribe on Amazon Bedrock + Claude + RAG:
“Claude has helped us cut writing times on CSRs by 90% so we can get documentation directly into human hands for review and approval.” — Waheed Jowiya, Digitalization Strategy Director, Novo Nordisk
NovoScribe expanding → device protocols, patient materials, full CTD automation.
Confirmed deployments: Sanofi, AbbVie, AstraZeneca, Genmab, BMS, Komodo Health, Axiom (toxicity via Claude Code + MCP DB servers).
Apr 2026: Coefficient Bio ~$400M all-stock, <10 FTE — Samuel Stanton, Nathan C. Frey from Genentech Prescient Design, «ASI for Science» thesis. Dimension investor: 38,513% IRR reported. Team under Eric Kauderer-Abrams — protein design + biomolecule modeling bridge to true AI drug discovery engine.
Mythos 5 drives these benchmarks — access severely restricted:
| Date | Export control status |
|---|---|
| June 12, 2026 | US Commerce bans foreign nationals from Fable 5/Mythos 5; global shutdown <90 min |
| June 26, 2026 | Partial restore: ~100 US critical-infrastructure orgs |
| June 30, 2026 | Fable 5 still offline; negotiations ongoing; general access not restored |
Multinational pharma teams — including non-US staff at today’s stage companies — face real ops uncertainty. See export control survival guide.
Can Jumper replicate AlphaFold at Anthropic? Genuinely uncertain. AlphaFold needed DeepMind infra, institutional partnerships, CASP benchmark. Anthropic = commercial LM company pivoting into scientific AI — Jumper knowledge invaluable, product breakthroughs need time + org alignment.
Anthropic multi-year bet: AI compresses drug discovery timelines at bedside — not just benchmarks. Claude for Life Sciences infra + Coefficient Bio + Karpathy pre-training + Jumper = coherent strategy. AlphaFold-scale breakthrough unknown — pieces more carefully assembled than most realize.
Biotech teams running Claude Code + MCP on long genomics/regulatory automation workflows: heavy Agent sessions on dedicated cloud Mac eliminate 16GB laptop swap thrashing, deliver stable SSH + Keychain isolation for macOS toolchain. NodeMini rental pricing + help center for setup. Corporate trajectory: Anthropic IPO guide.
Disclaimer: Data as of June 30, 2026 pre-livestream. Post-event update recommended for product announcements, Jumper official role, Fable 5 restore, new pharma partnerships. Not medical or investment advice.
The Briefing: AI for Science — livestream 30 июня 2026 (10:00 AM PST) из San Francisco. Anthropic showcase Claude for Life Sciences + demos/case studies от Novartis, BMS, Genentech и др.
John Jumper co-led AlphaFold 2 в Google DeepMind, Nobel Prize Chemistry 2024 в 39 лет. 19 июня 2026 объявил move в Anthropic после ~9 лет в DeepMind. Specific role undisclosed.
Internal testing: Claude Mythos 5 ~10× acceleration key drug design steps. Fully autonomous: viable candidates для 9/14 protein targets zero human assistance.
На 30 июня 2026 Mythos 5 только у ~100 vetted US orgs после partial restore 26 июня. Fable 5 offline с 12 июня. Stable Claude Code + MCP dev env: цены аренды cloud Mac.
Launch Oct 2025 — enterprise stack для pharma/biotech R&D. Connectors: Benchling, PubMed, 10x Genomics, Medidata, ClinicalTrials.gov — literature synthesis, hypothesis gen, clinical trial drafting, regulatory submissions.
Apr 2026 ~$400M all-stock. Sub-10 team из Genentech Prescient Design — protein design + biomolecule modeling, critical bridge LLM assistant → AI drug discovery engine.
NovoScribe на Amazon Bedrock + Claude + RAG templates. CSR writing time −90%. Expanding → device protocols, patient materials, full CTD automation.